In Vivo Anti-Mouse PD-1 Antibody (Mouse IgG2a, RMP1-14.1)

Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a Kappa | PA007162.m2a Ushelf

In Vivo Anti-Mouse PD-1 Antibody (Mouse IgG2a, RMP1-14.1)

$150.00 – $1,100.00

In stock
Catalog No.: PA007162.m2a | Isotype: Mouse IgG2a, Kappa | In Vivo Grade

$150.00 – $1,100.00

In vivo anti-mouse PD-1 antibody (mouse IgG2a, clone RMP1-14.1) — a recombinant chimeric mAb combining the identical variable region of the classic rat RMP1-14 clone with a mouse IgG2a κ Fc, retaining intact wild-type effector function (ADCC/CDC) for in vivo immune checkpoint blockade.

  • Target: Mouse PD-1 / CD279
  • Clone: RMP1-14.1 (identical variable region to rat RMP1-14)
  • Isotype: Mouse IgG2a, Kappa, intact Fc (ADCC/CDC)
  • Purity & Quality: >95% by SDS-PAGE; Endotoxin < 1 EU/mg (LAL)
  • Formulation: 0.2 μM sterile-filtered in 1× PBS
  • Applications: In Vivo Functional Blockade, Flow Cytometry (FC), IHC
  • Matching Isotype Control: Available
Clear
View cart
Catalog No. PA007162.m2a
Product Name In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2a Kappa
Data Sheet 📄 Download Product Data Sheet (PDF)
Supplier Name Syd Labs, Inc.
Brand Name Syd Labs
Synonyms Anti-Mouse PD-1, Anti-CD279, RMP1-14, RMP1-14.1, Mouse Anti-Mouse PD-1 mAb, Anti-PD-1 Mouse IgG2a
Summary The In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG2a Kappa Monoclonal Antibody (Clone RMP1-14.1) was produced in mammalian cells.
Clone RMP1-14.1, the same variable region sequences as the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14)
Isotype Mouse IgG2a, kappa
Applications In Vivo Functional Blockade (immune checkpoint blockade in syngeneic mouse models like MC38, CT26), Flow Cytometry (FC), IHC, Functional Assays
Immunogen The original rat hybridoma (clone name: RMP1-14) was generated by immunizing rats with mouse PD-1-transfected BHK cells.
Form Of Antibody 0.2 μM filtered solution of 1x PBS.
Endotoxin Less than 1 EU/mg of protein as determined by LAL method.
Purity >95% by SDS-PAGE under reducing conditions.
Shipping The In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG2a Kappa Monoclonal Antibody (Clone RMP1-14.1) are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 1 month from date of receipt, 2 to 8°C as supplied. 3 months from date of receipt, -20°C to -70°C as supplied.
Note Recombinant anti-mouse PD-1 / CD279 monoclonal antibodies, which combine the identical variable region sequence of the rat clone RMP1-14 with a mouse IgG2a constant region (chimeric format), are expressed in mammalian cells. Recombinant rat, chimeric mouse, and Fc-silent LALAPG mutant versions are also available.
Order Offline Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

References of Anti-Mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1)

The publications below use anti-mouse PD-1 clone RMP1-14.1 to investigate Fc domain interactions, effector function (ADCC/CDC), and PD-1⁺ cell depletion mechanisms — studies directly relevant to this mouse IgG2a κ format with intact wild-type Fc. Most studies used the parental RMP1-14 clone; where rat IgG2a was used, the identical antigen-binding variable region means functional conclusions are fully transferable.

1. Macrophages Impair TLR9 Agonist Antitumor Activity through Interacting with the Anti-PD-1 Antibody Fc Domain
Simone Camelliti, et al. Cancers (Basel) 2021. doi: 10.3390/cancers13164081
“We evaluated the contribution of macrophages to the effect of combinatorial immunotherapeutic treatments based on TLR9 stimulation (with CpG-ODNs) and PD-1 blockade in an ovarian cancer preclinical model. We observed a strong reduction in the antitumor efficacy of a TLR9 agonist upon anti-PD-1 antibody administration. Specifically, we found that TLR9-stimulated macrophages, through interacting with the fragment crystallizable (Fc) domain of the anti-PD-1 antibody, acquire an immunoregulatory phenotype leading to dampening of CpG-ODN antitumor effect.”

2. Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells
Yan Zhai, et al. J Control Release 2022. doi: 10.1016/j.jconrel.2022.07.010
“Anti-PD-1 antibodies are typically used to block inhibitory signals in dysfunctional T cells. Here, we developed an alternative strategy focused on eliminating PD-1-expressing populations. Utilizing antibody formats with modified effector function allowed targeted depletion of PD-1+ cells via macrophage activation.”

3. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia
Thanh T. Vu, et al. Pharmacol Res 2024. doi: 10.1016/j.phrs.2023.107048
“Cancer cachexia accelerates the clearance of multiple monoclonal therapeutic antibodies, reducing exposure. We assessed the specific contributions of target burden and FcRn-mediated recycling dynamics. Our findings outline that cachexia altered antibody elimination tracks independently of typical target receptor distributions.”

4. Diphtheria toxin‐derived, anti‐PD‐1 immunotoxin, a potent and practical tool to selectively deplete PD‐1+ cells
Tao Zhang, et al. Protein Sci 2023. doi: 10.1002/pro.4741
“Investigating the roles of chronic PD-1+ populations requires reliable depletion methods. We engineered a diphtheria toxin-based immunotoxin architecture targeting mouse PD-1 structures. This molecule mediates rapid, highly specific systemic elimination of active PD-1-positive subgroups inside immunocompetent strains.”

For more technical references or data sheets regarding the Recombinant Anti-Mouse PD-1 Monoclonal Antibody (Clone: RMP1-14.1) formats, including options from Syd Labs, please contact our scientific support team at message@sydlabs.com.

Other Formats

All variants below share identical RMP1-14.1 variable region sequences and mouse PD-1 (CD279) binding specificity. They differ only in Fc isotype and Fc effector function — choose the format that matches your experimental readout and mouse strain.

Catalog No. Isotype Fc Effector Function Host / Reactivity Applications
PA007162.r2a Rat IgG2a, kappa Intact (ADCC / CDC competent) Rat / Mouse IHC, FC, in vitro and in vivo functional assays
PA007162.m2a Mouse IgG2a, kappa Intact (ADCC / CDC competent) Mouse / Mouse IHC, FC, in vitro and in vivo functional assays
PA007162.m2c Mouse IgG2c, kappa Intact (ADCC / CDC competent) Mouse / Mouse IHC, FC, in vitro and in vivo functional assays
PA007162.m1 Mouse IgG1, kappa Low effector function Mouse / Mouse IHC, FC, in vitro and in vivo functional assays
PA007162.m2aLA Mouse IgG2a-L234A L235A P329G (LALAPG), kappa Fc-Silenced Mouse / Mouse IHC, FC, in vitro and in vivo functional assays, Fc-silenced neutralization
PA007162.m2cLA Mouse IgG2c-L234A L235A P329G (LALAPG), kappa Fc-Silenced Mouse / Mouse IHC, FC, in vitro and in vivo functional assays, Fc-silenced neutralization
PA007162.m1DA Mouse IgG1-D265A, kappa Fc-Silenced Mouse / Mouse IHC, FC, in vitro and in vivo functional assays, Fc-silent neutralization
PA007162.rt Rabbit IgG Rabbit Fc (non-mouse effector) Rabbit / Mouse IHC, FC, in vitro and in vivo functional assays

How to choose a format: Use an intact-Fc format (r2a, m2a, m2c, m1) when your readout may involve Fc-mediated effector activity, and note that mouse IgG2c matches the C57BL/6 (Igh-1b) allotype commonly used in MC38 and B16-F10 models, while mouse IgG2a matches BALB/c (Igh-1a) backgrounds such as CT26. Use an Fc-silenced format (m1DA, m2aLA, m2cLA) when you need pure PD-1 blockade without Fc-receptor engagement or ADCC/CDC confounding.

Ushelf Advisor

Research Reference Only — Compiled from peer-reviewed literature and Ushelf product specifications. Please verify critical parameters (dosing, working dilutions, buffer conditions) against the primary references, or confirm with our technical support before finalizing your experimental design.

Last updated: October 22, 2026.

Q: What is the difference between PA007162.m2a and the rat IgG2a version (PA007162.r2a)?

PA007162.m2a is a recombinant chimeric anti-mouse PD-1 (CD279) antibody. It retains the identical rat-derived variable region of clone RMP1-14, but pairs it with a wild-type mouse IgG2a kappa constant region instead of the rat IgG2a constant region of PA007162.r2a. This chimeric design ensures its Fc interactions are mouse-native and well-suited to mouse in vivo models, while maintaining native mouse IgG2a Fc effector functions like ADCC and CDC activities.

Q: Does PA007162.m2a possess intact Fc effector function compared to Fc-silenced variants?

Yes, unlike Fc-silent formats such as LALAPG or D265A mutants, PA007162.m2a retains native mouse IgG2a Fc gamma receptor binding and complement activation capabilities. This intact effector profile makes it specifically suitable for experimental applications where active immune engagement, cellular cytotoxicity, and Fc-mediated mechanisms are desired alongside immune checkpoint blockade of the PD-1/CD279 pathway in immunocompetent hosts.

Q: Is PA007162.m2a suitable for in vivo preclinical research?

Yes, it is produced in mammalian cells as an in vivo grade antibody featuring high purity (>95% by SDS-PAGE) and ultra-low endotoxin levels (<1 EU/mg by LAL method). It is commonly used for in vivo PD-1/CD279 blockade in syngeneic tumor models such as MC38, CT26, and B16, and is widely applied for flow cytometry (FC) and immunohistochemistry (IHC) applications in laboratory research.

Q: What specific clone characteristics and origin does PA007162.m2a have?

Designated as clone RMP1-14.1, this antibody shares identical variable region sequences with the classic rat anti-mouse PD-1 (CD279) clone RMP1-14. The original rat hybridoma was originally generated by immunizing rats with mouse PD-1-transfected BHK cells. This establishes its direct lineage from the well-characterized RMP1-14 parental clone, ensuring reliable target recognition for murine programmed cell death protein 1 studies.

Q: What is the recommended in vivo dosage for PA007162.m2a?

In mouse syngeneic tumor models, a standard dosage of 200 µg per mouse administered intraperitoneally every 3 days is commonly utilized, with a frequently cited effective experimental range spanning from 200 to 500 µg per mouse. However, the optimal dosage and administration schedule should always be carefully determined and optimized for each specific animal model, tumor cell line, and overall study design.

Q: Which isotype control should I use with PA007162.m2a?

A specialized mouse IgG2a, kappa isotype control formulated at a matching concentration and buffer composition is highly recommended for all in vivo and flow cytometry control experiments. Utilizing a proper matching isotype control ensures accurate baseline differentiation between target-specific checkpoint blockade and non-specific Fc interactions, and these matched control products are readily available for direct pairing.

Q: How do I choose between mouse IgG2a (PA007162.m2a) and mouse IgG2c (PA007162.m2c) for my mouse strain?

You should choose between mouse IgG2a (PA007162.m2a) and mouse IgG2c (PA007162.m2c) based strictly on your specific mouse strain’s endogenous immunoglobulin background. Strains such as BALB/c, C3H, and DBA/2 mice express IgG2a, whereas C57BL/6, C57BL/10, and NOD mice express IgG2c. Matching the antibody isotype precisely to the host strain helps prevent unwanted anti-isotype immune responses during studies.

Q: Are bulk packaging or custom formulations (such as carrier-protein free) available for PA007162.m2a?

Yes, bulk quantities and custom packaging options—including carrier-protein free or specific concentration adjustments—can be requested to support large-scale preclinical in vivo studies or specialized laboratory requirements. Please contact customer support or submit a formal inquiry to discuss specific project needs and batch availability.